- Rohrabacher is a longstanding advocate for the legalization of
medical cannabis
- Rohrabacher spearheaded historic U.S. legislation that protects
medical cannabis patients
TORONTO, May 29, 2019 /CNW/ - PharmaCielo Ltd.
("PharmaCielo" or the "Company") (TSXV:PCLO),
the Canadian parent of Colombia's
premier cultivator and producer of medicinal-grade cannabis oil,
PharmaCielo Colombia Holdings S.A.S., announced today that it has
enlisted former U.S. congressman and long-time medical cannabis
advocate Dana Rohrabacher as a
special advisor to the Company.
"Our team has received accelerated interest from players in
several legal U.S. states in recent weeks as the legal structure of
medicinal cannabis continues to evolve across the country," said
David Attard, Chief Executive
Officer of PharmaCielo. "We believe the U.S. is a significant
prospective market for PharmaCielo, particularly on the CBD side in
the near term, and we are delighted that Rep. Rohrabacher has
agreed to join our team as a special advisor. Rep. Rohrabacher has
been one of the most passionate advocates and influential forces in
support of legalized medical cannabis in the U.S., and we expect
his unparalleled knowledge and experience with understanding the
legislative environment to be invaluable to the company for U.S.
sales execution."
Dana Rohrabacher started his
political career as President Ronald
Reagan's special assistant and speechwriter. He was elected
as a U.S. representative from the state of California District 42 in 1988 and served in
Congress for nearly three decades. Rep. Rohrabacher is a
well-known advocate for the legalization of medical cannabis and
protection of medical cannabis patients' rights. He was one of the
driving forces behind the Rohrabacher-Farr Amendment,
pivotal legislation that became a milestone in the legalization of
medical cannabis at the crossroads between state and federal
levels. Rep. Rohrabacher was also one of the two Republican
cofounders of the Congressional Cannabis Caucus.
"As we look at the medicinal benefits of cannabis, with a
particular emphasis on its oil extracts, the United States needs to be able to
guarantee our citizens have access to the finest products available
from the global and domestic communities alike," said Rep.
Rohrabacher. "Having visited the PharmaCielo facilities and seen
firsthand the standards to which they produce and process oil
extracts, I am very engaged in helping them to understand U.S.
federal and state policy and patient medicinal needs, and helping
to address those needs in the future while continuing to set high
quality standards for the global marketplace overall."
With the appointment of Dana
Rohrabacher as special advisor, PharmaCielo continues to
bolster its roster of international advisors to support its
expansion into global markets, which has included a number of
notable experts including financial expert Jim Rogers, co-founder of the Quantum
Fund and Soros Fund Management. Earlier this month,
PharmaCielo also announced the establishment of an enhanced Medical
and Scientific Advisory Board, a renowned team of international
physicians, scientists and researchers led by Dr. Delon Human.
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO) is a global company, headquartered
in Canada, with a focus on ethical
and sustainable processing and supplying of all natural,
medicinal-grade cannabis oil extracts and related products to large
channel distributors. PharmaCielo's principal (and wholly owned)
subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered
at its nursery and propagation centre located in Rionegro,
Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by the use of words
such as "expects", "is expected", "intends", "believes", or
variations of such words and phrases or statements that certain
actions, events or results "may" or "will" be taken, occur or be
achieved. Forward looking statements include those relating to
the
U.S. market as a prospective market for CBD products in the
near-term. Forward-looking statements are based on
assumptions, including with respect to PharmaCielo's planned
products, and the ability to execute its business plan that
management believes is reasonable in the circumstances, but the
actual results, performance or achievements of PharmaCielo's
business may be materially different from any future results,
performance or achievements expressed or implied by any
forward-looking statements. Forward-looking statements can be
affected by known and unknown risks, uncertainties and other
factors, including, but not limited to, the equity markets
generally, risks associated with early-stage companies, risks
associated with the regulation of cannabis and cannabinoid
derivatives, failure to obtain necessary TSXV approval, competition
for PharmaCielo's planned products, risks associated with operating
in Colombia, and currency exchange
risk. Accordingly, readers should not place undue reliance on
forward-looking statements.
Except as required by law, PharmaCielo undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pharmacielo-gears-up-for-us-market-demand-enlists-former-congressman-and-medical-cannabis-advocate-dana-rohrabacher-as-a-special-advisor-300858134.html
SOURCE PharmaCielo Ltd.